Nasdaq

Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation

PRINCETON, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded a grant from the U.S. Food and Drug ...
Nasdaq

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

PRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed ...
Pharmabiz

Certara receives two new dermal virtual bioequivalence grants from US FDA

Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, has been awarded two new dermal virtual bioequivalence grants by the US Food ...
Business Wire

Simulations Plus Partners with Large Pharmaceutical Company to Develop the Virtual Bioequivalence Trial Simulator™ Module

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods ...
Seeking Alpha

Certara Simcyp™ Group Awarded Two New Grants from US FDA

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara (CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food and Drug ...